There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aurinia Pharmaceuticals (AUPH – Research Report) and Siemens Healthineers AG (SEMHF – Research Report) with bullish sentiments.
Aurinia Pharmaceuticals (AUPH)
In a report released yesterday, Stacy Ku from TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $11.00. The company’s shares closed last Tuesday at $8.13.
According to TipRanks.com, Ku is a 1-star analyst with an average return of
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $11.17, representing a 40.5% upside. In a report issued on November 11, Bloom Burton also maintained a Buy rating on the stock with a $10.85 price target.
See the top stocks recommended by analysts >>
Siemens Healthineers AG (SEMHF)
Kepler Capital analyst Oliver Reinberg maintained a Buy rating on Siemens Healthineers AG on November 18 and set a price target of EUR59.00. The company’s shares closed last Friday at $51.20, close to its 52-week low of $50.85.
Reinberg has an average return of
According to TipRanks.com, Reinberg is ranked #8921 out of 9184 analysts.
Currently, the analyst consensus on Siemens Healthineers AG is a Moderate Buy with an average price target of $62.50, representing a 22.1% upside. In a report issued on November 6, Jefferies also maintained a Buy rating on the stock with a EUR60.00 price target.
Read More on AUPH:
- Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines
- Aurinia Highlights Lupus Nephritis Breakthroughs at ACR 2024
- Aurinia Pharmaceuticals Engages at London Conference
- 3 Best Stocks to Buy Now, 11/11/2024, According to Top Analysts
- Aurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring
